Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML
A newly discovered vulnerability in leukemia cells could be exploited therapeutically while leaving healthy blood cells unharmed.
A novel non-canonical role for IL-23R was discovered in AML, where the receptor localizes intracellularly and regulates mitotic spindle assembly rather than cytokine signaling. Importantly, IL-23R depletion was selective for AML cells and spared normal hematopoietic progenitors, identifying a potential therapeutic vulnerability.
What the study was
- Study design
- Preclinical in vitro + primary AML samples (mechanistic study with BioID proteomics)
- Population
- AML cell lines and primary AML patient samples
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Leukemia
Why it surfaced
Highly novel mechanism (non-canonical intracellular cytokine receptor function in AML) with therapeutic selectivity for malignant over normal hematopoietic cells; preclinical only but supported by BioID proteomics and primary patient samples.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.